This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
A urine test for VPAC receptors (which bind vasoactive intestinal peptide and PACAP) on cancer cells detected prostate cancer with 96% sensitivity and no false positives in a cohort of 61 patients with elevated PSA.
Why it matters
Current prostate cancer screening with PSA has many false positives. A simple urine test with 96% sensitivity and zero false positives could reduce unnecessary biopsies.
The numbers in context
61 patients. Median age 65.3, median PSA 9.56 ng/mL. 25 (41%) had PCa on biopsy. VPAC urine test: 96% sensitivity (24/25), 4% false negative (1/25), 0% false positive. By PIRADS: 3/16 PCa in PIRADS 2, 7/21 in PIRADS 3, 7/14 in PIRADS 4, 8/8 in PIRADS 5.
How the study worked
Prospective study of 61 men ≥40 years with LUTS and PSA >4 but <15 ng/mL. Voided urine VPAC receptor testing and mp-MRI performed. All underwent 12-core TRUS-guided biopsy as reference standard.
Who was studied
Men ≥40 years with LUTS and PSA 4-15 ng/mL
What this study cannot tell us
Small sample (61 patients, 25 cancers). Single center. PSA 4-15 range only. Biopsy as reference may miss some cancers. VPAC test specifics (assay details) limited in abstract.
Read the original research
VPAC receptor positivity in comparison with mp-MRI in the diagnosis of prostate cancer: A preliminary study.
BJUI compass, 6(4), e70006
Citation
Setya, Nishant; Ghagane, Shridhar C; Nerli, Rajendra B; Bokare, Ashwin; Thakur, Madhukar L; Gomella, Leonard. (2025). VPAC receptor positivity in comparison with mp-MRI in the diagnosis of prostate cancer: A preliminary study.. BJUI compass, 6(4), e70006. https://doi.org/10.1002/bco2.70006